Abstract
Purpose
PET/CT has a major role in lymphoma imaging, but glycolytic activity in inflammatory processes can reduce specificity. In this study we evaluated restaging PET/CT findings in patients with non-Hodgkin lymphoma (NHL) and fat necrosis.
Methods
We identified 16 patients from 8,819 restaging FDG PET/CT scans with suspicion of or biopsy-proven fat necrosis on PET/CT.
Results
All patients had NHL and demonstrated focal FDG-avid nodular change on CT with density higher than that of fat but lower than that of soft tissue. Histological confirmation was obtained in eight patients, with high GLUT-1 staining between necrotic tissue and organizing fat necrosis evident. Uptake resolved in four patients, and surveillance was continuing in four without relapse.
Conclusion
Although rare, identification of fat necrosis in patients with a solitary FDG-avid nodule after therapy is important and may lead to the avoidance of unnecessary interventions or treatment. Specific features on CT aid identification, whilst follow-up imaging can be helpful as the metabolic abnormality regresses with time.
Similar content being viewed by others
References
Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H. Impact of FDG-PET/CT in the management of lymphoma. Ann Nucl Med. 2011;25:701–16. doi:10.1007/s12149-011-0549-0.
MacManus MP, Seymour JF, Hicks RJ. Overview of early response assessment in lymphoma with FDG-PET. Cancer Imaging. 2007;7:10–8. doi:10.1102/1470-7330.2007.0004.
Hicks RJ, Mac Manus MP, Seymour JF. Initial staging of lymphoma with positron emission tomography and computed tomography. Semin Nucl Med. 2005;35:165–75. doi:10.1053/j.semnuclmed.2005.02.003.
Hofman MS, Smeeton NC, Rankin SC, Nunan T, O’Doherty MJ. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009;50:1594–7. doi:10.2967/jnumed.109.064121.
McDermott S, Skehan SJ. Whole body imaging in the abdominal cancer patient: pitfalls of PET-CT. Abdom Imaging. 2010;35:55–69. doi:10.1007/s00261-008-9493-4.
De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, et al. Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging. 2009;34:696–711. doi:10.1007/s00261-008-9457-8.
Kapoor V, Fukui MB, McCook BM. Role of 18FFDG PET/CT in the treatment of head and neck cancers: posttherapy evaluation and pitfalls. AJR Am J Roentgenol. 2005;184:589–97.
Guy SD, Tramontana AR, Worth LJ, Lau E, Hicks RJ, Seymour JF, et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging. 2012;39:1348–55. doi:10.1007/s00259-012-2143-7.
Hollinger EF, Alibazoglu H, Ali A, Green A, Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med. 1998;23:93–8.
Ng AP, Wirth A, Seymour JF, Lee M, Hogg A, Januszewicz H, et al. Early therapeutic response assessment by (18)FDG-positron emission tomography during chemotherapy in patients with diffuse large B-cell lymphoma: isolated residual positivity involving bone is not usually a predictor of subsequent treatment failure. Leuk Lymphoma. 2007;48:596–600. doi:10.1080/10428190601099965.
Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A. Report on the Third International Workshop on Interim Positron Emission Tomography in Lymphoma held in Menton, France, 26-27 September 2011 and Menton 2011 consensus. Leuk Lymphoma. 2012;53:1876–81. doi:10.3109/10428194.2012.677535.
Adejolu M, Huo L, Rohren E, Santiago L, Yang WT. False-positive lesions mimicking breast cancer on FDG PET and PET/CT. AJR Am J Roentgenol. 2012;198:W304–14. doi:10.2214/AJR.11.7130.
Belakhlef A, Jani C, Church C, Fraser R, Lakhanpal S. Fat necrosis mimicking B-cell lymphoma: a PET/CT and FDG study. Clin Nucl Med. 2008;33:271–2. doi:10.1097/RLU.0b013e3181662bbf.
Singh AK, Gervais DA, Lee P, Westra S, Hahn PF, Novelline RA, et al. Omental infarct: CT imaging features. Abdom Imaging. 2006;31:549–54. doi:10.1007/s00261-005-0251-6.
Daskalogiannaki M, Voloudaki A, Prassopoulos P, Magkanas E, Stefanaki K, Apostolaki E, et al. CT evaluation of mesenteric panniculitis: prevalence and associated diseases. AJR Am J Roentgenol. 2000;174:427–31.
Horton KM, Lawler LP, Fishman EK. CT findings in sclerosing mesenteritis (panniculitis): spectrum of disease. Radiographics. 2003;23:1561–7. doi:10.1148/rg.1103035010.
Canyigit M, Koksal A, Akgoz A, Kara T, Sarisahin M, Akhan O. Multidetector-row computed tomography findings of sclerosing mesenteritis with associated diseases and its prevalence. Jpn J Radiol. 2011;29:495–502. doi:10.1007/s11604-011-0587-5.
Zissin R, Metser U, Hain D, Even-Sapir E. Mesenteric panniculitis in oncologic patients: PET-CT findings. Br J Radiol. 2006;79:37–43. doi:10.1259/bjr/29320216.
Joerger M, Nuessli DF, Henz S, Zaunbauer W, Cerny T, Cogliatti SB, et al. CT-diagnosed mesenteric alterations in patients with non-Hodgkin’s lymphoma: a population-based study. Onkologie. 2008;31:514–9. doi:10.1159/000151624.
Acknowledgments
We would like to thank Dr. M. Dickinson, Professor M. Prince and Associate Professor D. Ritchie for contributing cases. Dr. R. Kashyap was supported by Endeavour Awards, a venture of Austraining International in partnership with the Government of Australia.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kashyap, R., Lau, E., George, A. et al. High FDG activity in focal fat necrosis: a pitfall in interpretation of posttreatment PET/CT in patients with non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 40, 1330–1336 (2013). https://doi.org/10.1007/s00259-013-2429-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-013-2429-4